News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 169–180 of 243 stories

Laverock Therapeutics Launches In Vivo Programmes in Oncology and Genetic Medicine

Laverock Therapeutics has added in vivo programmes to its pipeline, extending its programmable gene control platform beyond ex vivo cell therapies. The programmes target in vivo CAR-T for solid tumours and in vivo gene silencing in genetic medicine, with an initial focus on nervous system disorders and metabolic disease.

Funding & Grants29 Sept 2026

52North Raises £3.2m to Transform Urgent Cancer Care

52North has raised £3.2m in a round co-led by Macmillan Cancer Support and Hargreave Hale AIM VCT, with participation from Cedars-Sinai Intellectual Property Company, Cancer Research Horizons, the University of Cambridge, OKG Capital and an Innovate UK grant. The funding will support clinical validation, regulatory progress and UK market introduction of Neutrocheck, its portable blood test for identifying chemotherapy patients at risk of neutropenic sepsis.

Redx Pharma Unveils Design of ROCKETEER Phase 2 Trial of RXC008 in Fibrostenotic Crohn's Disease

Redx Pharma has unveiled the design of ROCKETEER, a Phase 2 trial of its GI-restricted pan-ROCK inhibitor RXC008 in fibrostenotic Crohn's disease, with first patient enrolment expected in 2026. The randomised, placebo-controlled trial will enrol around 180 patients across North America, Europe and the UK, with a primary endpoint of change in stricture length on magnetic resonance enterography at week 24, an endpoint shaped by FDA input.

Tiziana Doses First Participants in Phase 2a BANYAN ALS Trial

Tiziana Life Sciences has dosed the first three participants in BANYAN, a Phase 2a trial of intranasal foralumab in ALS run within the Healey ALS MyMatch programme at Mass General Brigham. The 44-patient, placebo-controlled study is co-funded by the ALS Association and will assess safety and tolerability alongside biomarkers of regulatory T-cell activity.